Cartesian Therapeutics, Inc. (RNAC) is entering a catalyst-rich period as it advances Descartes-08, its RNA-engineered CAR-T therapy designed for autoimmune diseases, toward late-stage data and a potential regulatory filing. The company is also preparing to move its in vivo CAR-T platform into first-in-human evaluation, marking a second major pillar in its long-term strategy.
Descartes-08 is engineered using mRNA technology, enabling transient CAR-T activity without the prolonged immune suppression associated with traditional DNA-integrated CAR-T therapies. This approach is intended to offer safer, outpatient-friendly dosing for chronic autoimmune conditions such as myasthenia gravis, myositis, and juvenile dermatomyositis.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.